Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.
Joseph Mikhael, MD
Advertisement
Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO is a professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the chief medical officer of the International Myeloma Foundation (IMF).
Articles by Joseph Mikhael, MD
Joseph Mikhael, MD, MEd, discusses how the on-body injection option for isatuximab can improve convenience for community oncology staff and patients.
In an interview, Joseph Mikhael, MD, MEd, discusses the impact of the approval of subcutaneous isatuximab and its on-body delivery system in multiple myeloma.
Joseph Mikhael, MD, MEd, explains the function and potential benefits of the on-body injector now approved for use with isatuximab in multiple myeloma.
Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device.
Joseph Mikhael, MD, discusses the ongoing impact of daratumumab in the treatment landscape of patients with multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CAR T-Cell Therapy Delivers Durable QOL Gains at 2 Years
2
Neoadjuvant Anbenitamab Combination Improves pCR in ERBB2+ Breast Cancer
3
Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma
4
Dr Pant on Managing the Safety Profile of Daraxonrasib in Pancreatic Cancer
5